SAN DIEGO -- A novel therapy for polycythemia vera (PCV) maintained stable hematocrit levels for as long as 2.5 years and significantly reduced use of phlebotomy, a small randomized trial showed. The ...

Please provide your email address to receive an email when new articles are posted on . Aaron T. Gerds, MD, MS, spoke with Healio about the REVEAL study, results of which were presented at this year’s ...

Please provide your email address to receive an email when new articles are posted on . Induction therapy with twice-weekly rusfertide helped patients with polycythemia vera achieve target hematocrit ...

Credit: Thinkstock. The risk of hematocrit elevation may depend on testosterone therapy's route of administration, according to investigators. A rise in hematocrit levels occurs with 4 months of ...

Every year, millions of newborns—especially those born premature, underweight or sick—are at risk of neonatal hypoglycemia, a dangerous drop in blood sugar that can lead to seizures, brain injury and ...

Rusfertide effectively maintained hematocrit control below 45% and reduced phlebotomy eligibility in PV patients through 52 weeks. Patients switching from placebo to rusfertide achieved rapid and ...